ER | ApexOnco - Clinical Trials news and analysis

x

“OncologyPipeline is my favorite CI tool”

Monika Vogelmann

Head of Market Insights Oncology Europe

Daiichi Sankyo

Click here for more information

Regulatory

5 October 2023

Roche keeps expanding its SERD phase 3 programme

Trial results

31 August 2023

Olema takes its antagonist/degrader concept into phase 3

Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.

Subscribe to ER